Austin (Texas) [US], April 22 (ANI/PRNewswire): Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigatio
Austin [Texas], April 6 (ANI/PRNewswire): Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology, announces topline results from its first-in-human, multicenter, Phase II double-blind, placeb